U.S. Markets open in 5 hrs 59 mins

Array BioPharma Inc. (ARRY)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
11.320.00 (0.00%)
At close: 3:59PM EDT
People also watch
EXELCLDXARQLFOLDPGNX

Array BioPharma Inc.

3200 Walnut Street
Boulder, CO 80301
United States
303-381-6600
http://www.arraybiopharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees209

Key Executives

NameTitlePayExercisedAge
Mr. Ron Squarer BSc (Biochemistry), MBAChief Exec. Officer and Director1.06MN/A50
Mr. Andrew R. RobbinsChief Operating Officer684.38kN/A41
Dr. Victor Sandor M.D., C.MChief Medical Officer745.35kN/A51
Mr. Jason HaddockChief Financial OfficerN/AN/A47
Dr. Nicholas A. Saccomano Ph.D.Chief Scientific OfficerN/AN/A58
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

Corporate Governance

Array BioPharma Inc.’s ISS Governance QualityScore as of September 1, 2017 is 8. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.